Remedent, Inc. (REMI)
USD 0.03
(-17.14%)
USD 0.03
(-17.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -215.23 Thousand USD | 85.09% |
| 2023 | -1.44 Million USD | -174.51% |
| 2022 | -153.62 Thousand USD | 9101.06% |
| 2021 | 3760.00 USD | 100.49% |
| 2020 | -766.6 Thousand USD | -23.73% |
| 2019 | -619.57 Thousand USD | -1165.82% |
| 2018 | 69.25 Thousand USD | -94.37% |
| 2017 | -915.01 Thousand USD | 154.45% |
| 2016 | 165.68 Thousand USD | -12.87% |
| 2015 | 360.19 Thousand USD | -47.95% |
| 2014 | -497.25 Thousand USD | 285.69% |
| 2013 | -481.72 Thousand USD | -127.66% |
| 2012 | 2.54 Million USD | 707.3% |
| 2011 | 420.38 Thousand USD | 80.06% |
| 2010 | -2.22 Million USD | 23.82% |
| 2009 | -1.77 Million USD | 32.28% |
| 2008 | -2.76 Million USD | -116.6% |
| 2007 | -1.18 Million USD | 66.58% |
| 2006 | -3 Million USD | -1403.91% |
| 2005 | 923.39 Thousand USD | 4227.48% |
| 2004 | 743.22 Thousand USD | 99.28% |
| 2003 | -935.4 Thousand USD | 49.34% |
| 2002 | -1.88 Million USD | -157.41% |
| 2001 | -557.8 Thousand USD | 14.69% |
| 2000 | -865.18 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -120.21 Thousand USD | -452.22% |
| 2024 FY | - USD | 59.95% |
| 2024 Q1 | -18.79 Thousand USD | 92.57% |
| 2024 Q2 | -2690.00 USD | 16.98% |
| 2024 Q3 | 38.46 Thousand USD | 292.86% |
| 2023 Q4 | -75.44 Thousand USD | -28.52% |
| 2023 FY | - USD | -174.51% |
| 2023 Q3 | -58.7 Thousand USD | 57.51% |
| 2023 Q2 | -138.16 Thousand USD | -1050.86% |
| 2023 Q1 | 14.53 Thousand USD | 0.0% |
| 2022 FY | - USD | 9101.06% |
| 2021 FY | - USD | 100.49% |
| 2021 Q2 | 11.97 Thousand USD | -36.48% |
| 2021 Q3 | 110.85 Thousand USD | 825.55% |
| 2021 Q1 | 18.85 Thousand USD | 105.63% |
| 2020 Q4 | -334.66 Thousand USD | -134.32% |
| 2020 Q3 | -142.82 Thousand USD | 4.0% |
| 2020 Q2 | -148.77 Thousand USD | -4.99% |
| 2020 Q1 | -141.69 Thousand USD | -105.47% |
| 2020 FY | - USD | -23.73% |
| 2019 Q2 | -57.44 Thousand USD | 55.77% |
| 2019 Q4 | 2.58 Million USD | 1587.09% |
| 2019 Q3 | -174.15 Thousand USD | -203.19% |
| 2019 FY | - USD | -1165.82% |
| 2019 Q1 | -129.88 Thousand USD | 32.14% |
| 2018 Q2 | 90.9 Thousand USD | -5.82% |
| 2018 Q3 | 75.33 Thousand USD | -17.13% |
| 2018 Q4 | -191.41 Thousand USD | -354.09% |
| 2018 Q1 | 96.52 Thousand USD | 111.05% |
| 2018 FY | - USD | -94.37% |
| 2017 FY | - USD | 154.45% |
| 2017 Q2 | 95.91 Thousand USD | -31.43% |
| 2017 Q3 | 144.76 Thousand USD | 50.94% |
| 2017 Q4 | -873.67 Thousand USD | -703.51% |
| 2017 Q1 | 139.86 Thousand USD | 207.3% |
| 2016 FY | - USD | -12.87% |
| 2016 Q1 | 354.87 Thousand USD | 432.99% |
| 2016 Q4 | -130.35 Thousand USD | -260.46% |
| 2016 Q2 | 136.68 Thousand USD | -61.48% |
| 2016 Q3 | 81.23 Thousand USD | -40.57% |
| 2015 Q2 | 149.84 Thousand USD | -0.82% |
| 2015 Q4 | 66.58 Thousand USD | -27.67% |
| 2015 Q3 | 92.05 Thousand USD | -38.56% |
| 2015 Q1 | 151.08 Thousand USD | 122.54% |
| 2015 FY | - USD | -47.95% |
| 2014 Q2 | 36.53 Thousand USD | -74.58% |
| 2014 Q3 | 116.35 Thousand USD | 218.52% |
| 2014 FY | - USD | 285.69% |
| 2014 Q1 | 143.7 Thousand USD | -33.19% |
| 2014 Q4 | -670.18 Thousand USD | -675.96% |
| 2013 Q3 | -300.75 Thousand USD | 37.2% |
| 2013 FY | - USD | -127.66% |
| 2013 Q4 | 215.09 Thousand USD | 171.52% |
| 2013 Q2 | -478.87 Thousand USD | 35.03% |
| 2013 Q1 | -737.1 Thousand USD | -102.47% |
| 2012 Q2 | 254.83 Thousand USD | 1.9% |
| 2012 Q3 | 27.11 Thousand USD | -89.36% |
| 2012 Q4 | -364.05 Thousand USD | -1442.62% |
| 2012 FY | - USD | 707.3% |
| 2012 Q1 | 250.09 Thousand USD | 117.49% |
| 2011 Q3 | 400.99 Thousand USD | -35.22% |
| 2011 FY | - USD | 80.06% |
| 2011 Q1 | 791.18 Thousand USD | 271.87% |
| 2011 Q2 | 618.99 Thousand USD | -21.76% |
| 2011 Q4 | -1.42 Million USD | -456.52% |
| 2010 Q2 | -482.34 Thousand USD | -14.44% |
| 2010 Q4 | -460.34 Thousand USD | 38.49% |
| 2010 FY | - USD | 23.82% |
| 2010 Q1 | -421.49 Thousand USD | 71.32% |
| 2010 Q3 | -748.38 Thousand USD | -55.16% |
| 2009 Q3 | -3.13 Million USD | -175.49% |
| 2009 FY | - USD | 32.28% |
| 2009 Q4 | -1.46 Million USD | 53.05% |
| 2009 Q1 | 421.86 Thousand USD | 190.82% |
| 2009 Q2 | 4.14 Million USD | 883.13% |
| 2008 Q3 | -1 Million USD | -1.07% |
| 2008 Q1 | -299.27 Thousand USD | -350.67% |
| 2008 FY | - USD | -116.6% |
| 2008 Q4 | -464.49 Thousand USD | 53.97% |
| 2008 Q2 | -998.39 Thousand USD | -233.6% |
| 2007 Q4 | 119.38 Thousand USD | 120.84% |
| 2007 FY | - USD | 66.58% |
| 2007 Q3 | -572.85 Thousand USD | -3544.26% |
| 2007 Q2 | 16.63 Thousand USD | 102.02% |
| 2007 Q1 | -824 Thousand USD | -238.99% |
| 2006 Q4 | 592.86 Thousand USD | 135.44% |
| 2006 FY | - USD | -1403.91% |
| 2006 Q1 | 531.49 Thousand USD | 292.96% |
| 2006 Q2 | -317.23 Thousand USD | -159.69% |
| 2006 Q3 | -1.67 Million USD | -427.28% |
| 2005 Q3 | 252.97 Thousand USD | 16.89% |
| 2005 FY | - USD | 4227.48% |
| 2005 Q2 | 216.42 Thousand USD | -32.18% |
| 2005 Q1 | 319.09 Thousand USD | -12.29% |
| 2005 Q4 | 135.25 Thousand USD | -46.53% |
| 2004 Q4 | 363.81 Thousand USD | -7.58% |
| 2004 Q1 | 22.96 Thousand USD | 123.49% |
| 2004 Q2 | -35 Thousand USD | -252.43% |
| 2004 FY | - USD | 99.28% |
| 2004 Q3 | 393.67 Thousand USD | 1224.56% |
| 2003 Q1 | -138.27 Thousand USD | 81.04% |
| 2003 FY | - USD | 49.34% |
| 2003 Q4 | -448.97 Thousand USD | 10.25% |
| 2003 Q3 | -106.52 Thousand USD | 54.86% |
| 2003 Q2 | -241.33 Thousand USD | -74.54% |
| 2002 Q4 | -699.46 Thousand USD | -70.42% |
| 2002 FY | - USD | -157.41% |
| 2002 Q1 | -351.12 Thousand USD | -94.72% |
| 2002 Q2 | -409.48 Thousand USD | -16.62% |
| 2002 Q3 | -420.82 Thousand USD | -4.51% |
| 2001 FY | - USD | 14.69% |
| 2001 Q2 | -84.36 Thousand USD | 46.67% |
| 2001 Q3 | -138.01 Thousand USD | -66.98% |
| 2001 Q4 | -180.32 Thousand USD | -28.0% |
| 2001 Q1 | -158.19 Thousand USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 77.672% |
| Ansell Limited | 209.86 Million USD | 100.103% |
| Ansell Limited | 206.3 Million USD | 100.104% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 42.83 Million USD | 100.502% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 86.754% |
| Psykey, Inc. | -1.29 Million USD | 83.384% |
| ConvaTec Group Plc | 455.5 Million USD | 100.047% |
| ConvaTec Group Plc | 455.5 Million USD | 100.047% |
| Encision Inc. | -544.19 Thousand USD | 60.449% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -51.776% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -95.792% |
| Innovative MedTech Inc. | -7.67 Million USD | 97.195% |
| LifePoint, Inc. | -14.2 Million USD | 98.484% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 96.521% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 33.774% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 46.958% |
| SmileDirectClub, Inc. | -186.13 Million USD | 99.884% |
| Sector 10, Inc. | - USD | Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.048% |
| SheerVision, Inc. | -110.53 Thousand USD | -94.727% |
| United Health Products, Inc. | -2.5 Million USD | 91.398% |
| Vasamed, Inc. | -4.57 Million USD | 95.295% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 90.479% |
| Yubo International Biotech Limited | -1.17 Million USD | 81.724% |